N-(1-Methylcyclohexyl-1)propionamid | 24363-63-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(1-Methylcyclohexyl-1)propionamid
• 英文别名: N-(1-methylcyclohexyl)propanamide
• CAS: 24363-63-1
• 化学式: C₁₀H₁₉NO
• 分子量: 169.267
• InChiKey: UXUPPWRIVDWKSI-UHFFFAOYSA-N

物化性质

• 沸点：
  303.6±9.0 °C(Predicted)
• 密度：
  0.93±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-甲基-1-环己烯 、 丙腈 在 亚硝基硫酸 、 硫酸 作用下， 生成 N-(1-Methylcyclohexyl-1)propionamid
  参考文献：
  名称：

  Beger,J., Journal fur praktische Chemie (Leipzig 1954), 1969, vol. 311, p. 746 - 759

  摘要：

  DOI：

文献信息

• HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BI
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20150284371A1

  公开（公告）日：2015-10-08

  This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein R 1 and R 2 are independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or R 1 and R 2 together are —O—CH 2 — or -0- CF 2 —O—; R 3 is H, halogen, cyano, haloalkyl or haloalkyloxy; R 4 is C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl or C 3-6 cycloheteroalkyl, wherein the heteroatom is N or 0; R 5 is H or CH 3 ; R 6 is C 1-6 alkyl or C 3-6 cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.

  该申请描述了一种可以抑制清道夫受体B类，类型I（SR-BI）活性的化合物和方法，这些化合物和方法可以用于介导高密度脂蛋白（HDL）脂质摄取和治疗丙型肝炎病毒感染。这些化合物的化学式为：其中R1和R2独立地为H，卤素，氰基，卤代烷基，卤代烷氧基或OMe；或者R1和R2在一起为—O—CH2—或-0-CF2—O—；R3为H，卤素，氰基，卤代烷基或卤代烷氧基；R4为C1-6烷基，C3-6环烷基，C3-6环烷基甲基或C3-6环杂烷基，其中杂原子为N或O；R5为H或CH3；R6为C1-6烷基或C3-6环烷基；而A、B、D和E分别独立地为CH、N、O或S，其中至少一个为N，另一个为N、O或S。
• Benzolactam compounds as protein kinase inhibitors
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US11001575B1

  公开（公告）日：2021-05-11

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  本发明提供了一种式 (0) 的化合物： 或其药学上可接受的盐、N-氧化物或同系物；其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N； R1 选自 -(Alk1)t-Cyc1；其中 t 为 0 或 1； 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个氟原子取代的 C1-3 烃基； R3 是氢或基团 L-R7； R4 选自氢、甲氧基和任选被取代的 C1-3 烷基；以及 R4a 选自氢和 C1-3 烷基； 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义；只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂，可用于治疗 ERK1/2 介导的疾病。因此，这些化合物可用于治疗，特别是治疗癌症。
• SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2780337B1

  公开（公告）日：2017-12-20
• NEK6 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF SOLID TUMORS
  申请人：CONSIGLIO NAZIONALE DELLE RICERCHE

  公开号：US20210147395A1

  公开（公告）日：2021-05-20

  The mitotic kinases regulating the dynamics of centrosomes and the functions of the mitotic spindle are potential targets for the antitumour therapy. In the present invention some molecules with inhibitory activity on NEK6 have been identified. The present invention relates to such molecules and to the compositions including them for use as inhibitors of NEK6 in a method of treatment of tumours both in monotherapy and in combinations with other drugs.
• US5780473A
  申请人：——

  公开号：US5780473A

  公开（公告）日：1998-07-14